tions were suggested on an asneeded basis . However, the patient was lost to follow-up for 6 months. When she did return, examination revealed that her vocal fold mobility was normal, and laryngovideostroboscopy revealed that her mucosal waves were normal bilaterally ( figure 3 ). Nevertheless, examination also detected muscle tension dysphonia, and the patient underwent two sessions of voice therapy . Thereafter, her examination findings were completely normal ; and she reported a normal voice without limitations.
The two most likely reasons for a sudden onset of hoarseness following orotracheal intubatio n are recurrent laryngeal nerve paralysis and cricoarytenoid dislocation. Differentiating between these two possibilities can be facilitated by the use of laryngeal EMG. IfEMG shows norma l nerve activity, a reduction of the dislocated arytenoid should be performed as soon as possible. Vocal fold paralysis following orotracheal intubation is believed to be caused by a compression injury to the recurrent laryngeal nerve by the cuff of the endotracheal tube. Our experience with vocal fold paralysis following orotracheal intubation includes several patients whose laryngeal EMG findings suggested a poor prognosis, but who subsequently experienced a spontaneous recovery of vocal fold motion.
Gelfoam is made up of bovine gelatin, and it is supplied sterile as either a powder or a foam sheet. The powder can be mixed with 3 to 5 ml of sterile saline to form a paste for vocal fold injection.' Likewise, the foam sheeting can be A 35-year-old woman, a nurse, sought evaluation for hoarseness of 35 days' duration. Her hoarseness had begun suddenly following a surgical procedure to close an infected wound of the coccyx. The surgery had been performed with the patient under general an'esthesia and orotracheal intubation. The procedure had been performed without difficulty .
On our examination, laryngovideostroboscopy revealed immobility of the left true vocal fold (figure 1). No other abnormalities were noted. The patient's Voice Handicap Inventory (VHI) score was 69. Laryngeal electromyography (EMG) was performed on the same day to rule Figure 1 . Laryngovideostroboscopy detects out a cricoarytenoid dislocation, and the paralysis of the left true vocal fold, those findings were consistent with a left recurrent laryngeal neuropathy. With the patient under local anesthesia and intravenous sedation, Gelfoam was injected into the left true vocal fold to achieve temporary medialization. Following the injection, the patient reported that her voice and swallowing functions were significantly improved. Her VHI score fell to 48 . Examination at 6 days postoperatively revealed a wellmedialized left true vocal fold (figure 2).
At the 6-week follow-up, however, no movement of the left true vocal fold was noted . A repeat laryngeal EMG identified fibrillation potentials at rest and no motor unit activation on attempted phonation. These findings were consistent with severe left recurrent laryngeal neuropathy. The prognosis for a spontaneous recovery was unfavorable.' Given that only 3 months had passed since the onset of the vocal fold paralysis, repeat Gelfoam injec-In clinical trials, commonly reported adverse events with RHINOCORT AQUA versus vehicle placebo were epistaxis (8% vs 5%), pharyngitis (4% vs 3%), bronchospasm (2% vs 1%), coughing (2% vs < 1%), and nasal irritation (2% vs < 1%). The overall incidence of adverse events with RHINOCORT AQUA was similar to that observed with vehicle placebo. HOW SUPPLIED: RHINOCORT AQUA Nasal Spray 32mcg is availablein a green coated glass bottle witha metered·dose pump spray and a green protection cap. RHINOCORT AQUA Nasal Spray 32 mcg prO Vides 120 metered sprays afte r ini tial primi ng; netfill weight 8.6g. TheRHINDCORT AQUA Nasal Spray ,32 mcg bottle has been filled with an excess to accommodate the priming activity. The bott le should be discarded afte r 120 sprays following initial priming, since the amount of budesonide delivered per sp r a~thereafter may be substantially lessthan the labeled dose. Each spray delivers 32mcg of budesonide tothe patient.
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Rev. 10101 205359 Alltrademarksarethe property oftheAstraZeneca group © AstraZeneca2002 mended daily intranasal dose in adultsand children on a mcg/m 2 basis). Budesonide was not mutagenic or clastogenic in sixdiffer ent test systems: Ames, Salmonella/microsome plate test, mouse micronucleus test, mouse lymphoma test, chromosome aberration test inhuman lymphocytes, sex-linked recessive.lethal test m Drosophila melanogaster , and DNA repair analysis m rat hematocyte cul ture. In rats, budesomde caused a decrease in prenat al viability and viability of the pups at birthand duringlactation, along with a decrease m maternai body-weightgain,atsubcutaneous doses of20mcg/kg and above (less than themaximum recommendeddaily intranasal dose inadults onamcg/m 2 basis) . No such effectswerenoted at5 mcglkg(less than the maximum recommended daily intranasal dose in adults ona mcg/m 2 basis). Pregnancy: Teratogemc Effects: Pregnancy Category C: Budesonide was teratogenic and embryocidal in rabbits and rats. Budesomde produced fetal loss, decreased pup weights, and skeletal abnormalities at subcutaneousdoses of 2,5 mcg/kg in rabbi tsand500 mcg/kgin rat s (approxi mately2and 16times themaximumrecommended dallymtranasal dose in adults on a mcg/m 2 basis). Inanother study in rats, noteratogenic or embryocidal effectsĨ e r e seen at inhalation doses upto 250 mcg/kg (approximately 8 times the maximum recommended daily mtranasal dose in adults on a mcg/m2 basis). Thereare noadequate and well-controlled studies in pregnant women. RHINOCORT AQUA Nasal Spray should be used during pregnancy only if the potent ial benefit Justifies the potentialrisk to the fetus. Experience with oralcorticosteroidssince their introduction in pharmacoloqtc, as opposed to physiologic, doses suggests that rodents are more prone to teratogemc effects from COrtiCOsteroidsthan humans. In addition, because there IS a natural mcrease m corticosteroid production dUring pregnancy, most women will requi rea lower exogenous corticosteroid dose and many wi".notneed COrtiCOsteroid treatment during preg nancy. BRIEFSUMMARY INDI CATI ONS AND USAGE RHINOCORT AOUA Nasal Spray is indicated for the management of nasal symptomsof seasonal or perennialallergic rhinitis in adults and chi ldren sixyears ofage and older. CONTRAINDICATIONS Hypersensitivity 10any oftheingredients in thispreparation contraindicates the use of RHINOCORT AQUA Nasal Spray. WARNINGS Thereplacement of asystemic corticosteroidwi thatopical corticosteroidcan be accompanied by signs ofadrenal insufficiency, and in addition some patients may experience symptoms of corticosteroid withdrawal, eg, joint and/or muscular pain, lassitude, and depression. Patients previously treated for prolonged periods wi thsystemiccorticosteroidsand transferred totopical corticosteroidsshouldbe carefully monitored for acuteadrenal insufficiency inresponse tostress. Inthose patients who have asthma orother cl inical conditions requiring long-termsystemic corticosteroidtreatment, too rapidadecrease insystemic corticosteroidsmay cause asevere exacerbation oftheir symptoms. Patientswho are on drugs which suppress theimmune system aremore susceptible toinfections than healthy individuals. Chickenpoxand measles, forexample,canhave amoreserious oreven fatal course in non·immune children oradults on immunosuppressant doses ofcorticosteroids. In such children oradultswhohavenothad these diseases, particularcare should be taken toavoid exposure. How the dose, route, and duration ofcorticosteroid administration affects the risk ofdeveloping a disseminated infection is not known. Thecontribution ofthe underiying disease and/or prior corticosteroid treatmenttothe risk is also not known. Ifexposed tochicken pox, prophylaxiswithvaricella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package insertsforcompleteVZIG and IG prescribing information). If chicken pox develops, treatment withantiviral agents may be considered. Spray should receivethe followi ng information and instructions. Patients who are on immunosuppressant doses of corticosteroidsshould be warned to avoi d exposureto chicken pox or measles and, il exposed, to obtai nmedical advice. Patients shoulduseRHINOCORT AQUA Nasal Spray at regular intervalssinceits effectiveness depends on its regular use (see DOSAGE AND ADMINISTRATION). An improvement in nasal symptoms may benoted in patientswithin 10 hours of first using RHINOCORTAQUA Nasal Spray. This time to onset is supported by anenvironmental exposure unit study in seasonal allergic rhinitis patients whi ch demonstratedthatRHINOCORTAQUA Nasal Spray led toastatistically signi ficant improvement innasal symptomscomparedtopl aceboby10hours. Further support comes fromaclinicalstudyof patientswit hperennial allergic rhini tis which demonstrated a stat istically si gni ficant improvement in nasal symptoms for both RHI NOCORT AQUANasal Spray and fortheact ive comparator (mometasone furoate) compared topl acebo by 8hours. Onset wasalso assessedinthis study with peak nasal inspiratory f10¥/ rate and thisendpoint failed to show efficacy forei ther activetreatment. Although stat isti cally significant improvements in nasal symptoms compared topl acebo werenoted within 8-10hours in thesestudies, about one hallto two thirds of the ultimatecli nical improvement withRHINOCORT AQUA Nasal Spray occursover thefirst 1-2days, andmaximum benefit may not be achieved until approximately 2 weeks after initiation of treatment. Initialassessment for responseshould be made during this time frame and periodically untilthepatient's symptoms are stabilized. cut into small pieces and mixed vigorously with 3 to 5 ml of saline to form an injectable paste . Gelfoam has a long history of successful, uncomplicated use in many surgical settings.
PRECAUTIONS: General
Optimal results with Gelfoam vocal fold injection are achieved when the injection is placed deep to the vocal fold, adjacent to the thyroid lamina. Gelfoam vocal.foldin-jections can be administered in the operating room with the patient under general anesthesia or in the office (perorally or percutaneously) with the aid of local anesthesia.
Temporary medialization of a paralyzed vocal fold with Gelfoam injection is an excellent method when the prognosis for recovery is unknown.' It provides medialization for 4 to 6 weeks, and it can be repeated if necessary without any permanent side effects. 
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